medication surveillance
Recently Published Documents


TOTAL DOCUMENTS

12
(FIVE YEARS 1)

H-INDEX

3
(FIVE YEARS 0)

2021 ◽  
Vol 145 ◽  
pp. 104329
Author(s):  
Florine A. Berger ◽  
Heleen van der Sijs ◽  
T. van Gelder ◽  
Aaf F.M. Kuijper ◽  
Patricia M.L.A. van den Bemt ◽  
...  

2020 ◽  
Vol 62 (4) ◽  
pp. 260-262
Author(s):  
Laura E. Breeher ◽  
Heather L. Stonelake-French

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sun Mi Shin ◽  
Hong-Ah Kim ◽  
Inmyung Song ◽  
Ha-Lim Jeon ◽  
Ju-Young Shin

Abstract Background Since December 2010, a nationwide real-time medication surveillance program has been implemented in Korea to prevent potential adverse drug reactions. Our goal was to evaluate physicians’ and pharmacists’ satisfaction and clinical needs for the medication surveillance program in Korea. Methods Both web- and paper-based surveys were conducted using a structured questionnaire among 1164 physicians and pharmacists from May 23, 2014 to August 11, 2014. The survey consisted of questions about the participant’s satisfaction with the medication surveillance program, clinical usefulness, clinical need for the medication surveillance program, and sociodemographic characteristics. Multivariate ordinal logistic regression was performed to investigate the factors influencing satisfaction levels with the medication surveillance program. Results We analyzed data from 1120 respondents, including 503 physicians and 617 pharmacists. Overall, 63.1% of the respondents were satisfied with the medication surveillance program. Pharmacists were more satisfied with the program than were physicians (69.1% vs. 55.6%; adjusted odds ratio, 2.13; 95% confidence interval, 1.65–2.76). Among the respondents, 77.8% cited a decrease in therapeutic duplication to be a major improvement resulting from the medication surveillance program, 82.6% considered the drug–drug interaction information useful, and 48.7% suggested that the program should include information on liver or kidney disease–drug interaction. Conclusions Overall, 63.0% of physicians and pharmacists were satisfied, and a decrease in therapeutic duplication was regarded as the most beneficial component. Further improvements by considering clinical needs of physicians and pharmacists will be needed to increase satisfaction.


2016 ◽  
Vol 27 ◽  
pp. vi519
Author(s):  
A.E. Ramos-Esquivel ◽  
A. Viquez-Jaikel ◽  
C. Fernandez ◽  
Z. Zeledon ◽  
F. Jimenez ◽  
...  

2013 ◽  
Vol 28 (1) ◽  
pp. 93-98 ◽  
Author(s):  
Maria Padron ◽  
Marta A. Miyares

Pharmacist-directed anticoagulation management services (AMSs) have been shown to significantly lower anticoagulation-related mortality, length of hospital stay, bleeding complications, blood transfusion requirements, and cost of therapy. AMSs are only 1 component of an anticoagulation stewardship program. Frequently, stewardship programs are limited to inpatient populations. Incorporating components that facilitate transition to outpatient status will ideally encompass complete care. The purpose of this program was to expand anticoagulation services and standardize care by implementing a full-service stewardship program including a transition of care service. The first component of the study involved medication surveillance for inpatients on anticoagulation therapy. The second component involved transitioning patients on anticoagulation, primarily with venous thromboembolism (VTE) to outpatient management. Finally, the pharmacist identified areas for optimization. Optimization involved developing or updating protocols to reflect updates in the literature as well as updating institution-specific information resources. Interventions made through medication surveillance and utilization of the VTE transition of care services translated into a total cost savings of approximately US$270 320. A postgraduate, first-year pharmacy resident contributed to improving patient outcomes while reducing utilization of hospital services and obtaining substantial cost savings through participation in anticoagulation stewardship services.


2013 ◽  
Vol 35 (4) ◽  
pp. 554-559 ◽  
Author(s):  
Brigit van Oijen ◽  
Rob Janknegt ◽  
Hugo de Wit ◽  
Frank Peters ◽  
Harry Schouten ◽  
...  

2006 ◽  
Vol 2 (2) ◽  
pp. 78-82 ◽  
Author(s):  
Dustin D. French ◽  
Andrea Spehar ◽  
Robert Campbell ◽  
Thomas N. Chirikos ◽  
Tatjana Bulat ◽  
...  

2005 ◽  
Vol 39 (10) ◽  
pp. 1720-1725 ◽  
Author(s):  
JW Foppe van Mil

OBJECTIVE: To describe the pharmaceutical care activities and research in community pharmacy in the Netherlands. FINDINGS: Pharmaceutical care is well advanced in Dutch pharmacy practice. This is largely due to the fact that clinical pharmacy was already an integrated part of community pharmacy practice by the end of the 1980s. Activities of the International Pharmaceutical Federation (FIP), some wholesale companies, and influential individuals in the Netherlands stimulated universities and the Royal Society for the Advancement of Pharmacy to advance the implementation of pharmaceutical care. DISCUSSION: Not all pharmacies in the Netherlands provide pharmaceutical care at the same level, although medication surveillance (concurrent and prospective medication analysis) is part of everyday practice. Implementation of quality assurance systems in community pharmacy practice could be helpful in assuring high levels of care. Similar to those in other countries, Dutch pharmacists are torn between the wish to provide pharmaceutical care and economic considerations, although the financial status of most pharmacies is still (very) healthy. New entrants into the market, such as supermarket and pharmacy chains, seem to put little emphasis on care provision. CONCLUSIONS: Pharmaceutical care has been implemented in many Dutch community pharmacies, but not everywhere to the same extent. Due to excellent automated medication surveillance; structured, high-quality medication counseling; and the fact that patients usually visit the same pharmacy, Dutch patients are well protected against many drug-related problems.


Sign in / Sign up

Export Citation Format

Share Document